• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Cochlear (ASX:COH) FDA Approval Of Its Rechargeable Osia 3 Processor

    Simply Wall St·07/14/2026 16:38:11
    Listen to the news
    • Cochlear Limited has received FDA clearance for its Osia 3 Sound Processor, the first fully rechargeable active bone conduction sound processor, offering up to 30 hours of battery life, broader fitting ranges, and expanded connectivity including Auracast broadcast audio.
    • Clinical research indicating high patient satisfaction and improved speech understanding, combined with backwards compatibility for existing Osia users, positions Osia 3 as a meaningful enhancement to Cochlear’s upgrade ecosystem and service-led model.
    • We’ll now examine how Osia 3’s fully rechargeable design and broader connectivity options may influence Cochlear’s existing investment narrative and outlook.

    The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Cochlear Investment Narrative Recap

    To own Cochlear, you generally need to believe in the long-term demand for implantable hearing solutions and the value of its recurring upgrade and services model. The Osia 3 launch strengthens that upgrade story in the U.S., but does not directly resolve near-term earnings pressure from softer growth, pricing headwinds in China and higher fixed costs, which remain the key short-term risks to watch.

    Among recent announcements, the earlier launch of the Baha 7 and SoundBand in 2025 is especially relevant, as it shows Cochlear expanding its bone conduction and non-surgical portfolio alongside Osia 3. Together, these products could support system volumes and the installed base over time, but they also sit against a backdrop of higher R&D and manufacturing costs that are already weighing on margins.

    Yet, while products like Osia 3 look encouraging, investors should be aware that...

    Read the full narrative on Cochlear (it's free!)

    Cochlear's narrative projects A$2.7 billion revenue and A$402.8 million earnings by 2029. This requires 4.4% yearly revenue growth and about A$57.5 million earnings increase from A$345.3 million today.

    Uncover how Cochlear's forecasts yield a A$124.40 fair value, in line with its current price.

    Exploring Other Perspectives

    ASX:COH 1-Year Stock Price Chart
    ASX:COH 1-Year Stock Price Chart

    Some of the lowest-estimate analysts were assuming only 3.4% annual revenue growth and A$373.2 million of earnings by 2029, so compared with the baseline risks around pricing and upgrade cycles, they frame Osia 3 against a much more cautious view of how quickly new products and referral efforts might translate into meaningful financial improvement.

    Explore 6 other fair value estimates on Cochlear - why the stock might be worth as much as 43% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Want Some Alternatives?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.